In breast cancer, lung cancer, bladder cancer, and colon cancer, GLO1 gene amplification was significantly associated with poor survival outcomes, suggesting that GLO1 could be used as a biomarker for poor prognosis (148, 149). Here, GLO1 is linked to lung cancer.